The structure and function of the glucagon-like peptide-1 receptor and its ligands

被引:211
|
作者
Donnelly, Dan [1 ]
机构
[1] Univ Leeds, Fac Biol Sci, Leeds LS2 9JT, W Yorkshire, England
关键词
GLP-1; GPCR; exendin-4; exenatide; liraglutide; diabetes; glucagon; insulin; VASOACTIVE-INTESTINAL-PEPTIDE; GUINEA-PIG PANCREAS; N-TERMINAL DOMAIN; GLP-1; 7-36; AMIDE; IN-VITRO; INSULIN-SECRETION; DISPERSED ACINI; EXTRACELLULAR DOMAIN; PARATHYROID-HORMONE; BIOLOGICAL-ACTIVITY;
D O I
10.1111/j.1476-5381.2011.01687.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-residue peptide hormone released from intestinal L cells following nutrient consumption. It potentiates the glucose-induced secretion of insulin from pancreatic beta cells, increases insulin expression, inhibits beta-cell apoptosis, promotes beta-cell neogenesis, reduces glucagon secretion, delays gastric emptying, promotes satiety and increases peripheral glucose disposal. These multiple effects have generated a great deal of interest in the discovery of long-lasting agonists of the GLP-1 receptor (GLP-1R) in order to treat type 2 diabetes. This review article summarizes the literature regarding the discovery of GLP-1 and its physiological functions. The structure, function and sequenceactivity relationships of the hormone and its natural analogue exendin-4 (Ex4) are reviewed in detail. The current knowledge of the structure of GLP-1R, a Family B GPCR, is summarized and discussed, before its known interactions with the principle peptide ligands are described and summarized. Finally, progress in discovering non-peptide ligands of GLP-1R is reviewed. GLP-1 is clearly an important hormone linking nutrient consumption with blood sugar control, and therefore knowledge of its structure, function and mechanism of action is of great importance.
引用
收藏
页码:27 / 41
页数:15
相关论文
共 50 条
  • [31] Can epicardial fat glucagon-like peptide-1 receptor open up to the cardiovascular benefits of glucagon-like peptide-1 analogues?
    Iacobellis, Gianluca
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (03): : 224 - 225
  • [32] Metabolic responses and benefits of glucagon-like peptide-1 (GLP-1) receptor ligands
    Tanday, Neil
    Flatt, Peter R.
    Irwin, Nigel
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (04) : 526 - 541
  • [33] Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism
    Hansen, Morten S. S.
    Tencerova, Michaela
    Frolich, Jacob
    Kassem, Moustapha
    Frost, Morten
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 25 - 37
  • [34] Glucagon-like peptide-1 receptor expression and its functions are regulated by androgen
    Zhu, Liying
    Zhou, Jinxing
    Pan, Yu
    Lv, Jing
    Liu, Yang
    Yu, Shanhe
    Zhang, Yifan
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 120
  • [35] Glucagon-like peptide-1 and satiety
    S. R. Bloom
    Nature, 1997, 385 : 214 - 214
  • [36] Structure-function analysis of a series of glucagon-like peptide-1 analogs
    Parker, JC
    Andrews, KM
    Rescek, DM
    Massefski, W
    Andrews, GC
    Contillo, LG
    Stevenson, RW
    Singleton, DH
    Suleske, RT
    JOURNAL OF PEPTIDE RESEARCH, 1998, 52 (05): : 398 - 409
  • [37] Glucagon-Like Peptide-1 and Diabetes
    Monami, Matteo
    EXPERIMENTAL DIABETES RESEARCH, 2011,
  • [38] Glucagon-like peptide-1 and satiety
    van, Dijk, G.
    Thiele, T.E.
    Seeley, R.J.
    Woods, S.C.
    Bernstein, I.L.
    Bloom, S.R.
    Nature, 1997, 385 (6613)
  • [39] Glucagon-like peptide-1 and satiety
    G. van Dijk
    T. E. Thiele
    R. J. Seeley
    S. C. Woods
    I. L. Bernstein
    Nature, 1997, 385 : 214 - 214
  • [40] Is Glucagon-like peptide-1 for real?
    Murr, Michel M.
    SURGERY FOR OBESITY AND RELATED DISEASES, 2014, 10 (05) : 786 - 786